3070411-10-5
Chemical Structure
Cbl-b-IN-29
- CAS No.: 3070411-10-5
- Formula:C30H34FN5O
- Molecular Weight:499.62
InChIKey: MMQKLBZMBNKKBF-CVOJIUGNSA-N
SMILES: CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1
Biological Activity: Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cbl-b-IN-29 | Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
